Welcome to Mesothelioma.net - Turning Hope and Faith into Action.

Verastem Mesothelioma Trials Continue to Inspire Optimism

Researchers investigating the efficacy of Verastem’s new drug, defactinib, continue to express enthusiasm and optimism about the drug’s usefulness following early results from an ongoing international clinical trial. Defactinib, also known as VS-6063, is one of the most promising drugs that are currently being tested in the search for a cure for mesothelioma, a rare and always fatal form of cancer that is caused by exposure to asbestos. Patients who are diagnosed with mesothelioma generally have a life expectancy of less than two years following diagnosis. Defactinib is manufactured by Verastem, and is being tested for mesothelioma, as well as for ovarian cancer and non-small-cell lung cancer in its second phase of clinical trials. There are currently about 180 patients enrolled in the trial across over a dozen countries. The drug’s goal is the killing of stem cells, which are known to cause metastasis and tumor recurrence. According to Verastem’s Chief Financial Officer Robert Forrester, “We’re onto something really important here. We beliee we have the opportunity to change the way cancer is treated and to make a significant difference in the lives of many patients. Our confidence in each of these drugs continues to grow. The outlook has been grim for a patient with mesothelioma. The good news is that targets in treatment are clearly emerging. There is increasing confidence now that 6063 is a drug that can help many patients. We’ve seen what is happening.”

Stem cells make up a very small portion of a mesothelioma tumor, and yet they have been found to play a large role in the cancer’s resistance to chemotherapy. Defactinib’s impact lies in its ability to block a specific protein within the stem cells called Focal Adhesion Kinase. By doing this, it stops the cancer from growing. The drug is given in combination with Alimta, which at this point is the only FDA-approved drug for the treatment for mesothelioma.

The international study is being done in several cities across the United States, including Philadelphia, New York, Baltimore, Chicago and San Francisco. Patients are still being recruited for the trials, which hope to attract a total of 372 patients by the end of 2015.

Terri Oppenheimer

Terri Oppenheimer is an experienced blog writer, editor, and proofreader. She graduated from the College of William and Mary with a degree in English. She specializes in providing content for websites and finds tremendous enjoyment in the things she learns while doing her research. Her specific areas of expertise include health, medical research, and law.

Get Your FREE Resources Sent Overnight

  • New treatment options
  • Veterans benefits & claims
  • $30 Billion asbestos trust fund information

– Or Call –

Site Navigation

Where can I

Get Additional Help?

For over 15 years, we’ve provided the best FREE resources to mesothelioma patients and loved ones. Our resources include information on the leading treatment options and best doctors in your area; lessons learned from survivors; claims and benefits specifically for Veterans; and how to access your share of billions of dollars in trust fund money.

Get Your FREE Resources Sent Overnight

  • New Treatment Options
  • Veteran's Benefits & Claims
  • $30 Billion Asbestos Trust Fund Information

– Or Call –

We are here to help you


If you've been diagnosed with asbestos-related cancer, contact us at 1-800-692-8608 to find out if you are eligible to receive compensation. You can also fill out the form above to receive FREE information.

Quick Compensation - $30 Billion Trusts
$30 Billion Asbestos Trusts
Get Started